GrandAdmiralThrawn, with GCAN, here's what got me wondering...
That might be so and there is no evident reason to the market to go from negative to positive with GCAN. The proof is where the price had dropped. Regardless to what I am saying, that is the market talking. That was why I stated in my post... I would maybe wait to see exactly what's coming in here to be more sure for your own edification. Most of the times within the market, reverse splits are bad news, but every so often, sometimes they work out good for the shareholders. Especially when nearly the entire OS is owned by the CEO and Insiders like here with GCAN .
Something that got me wondering is that within the PRE-14C filed with the SEC yesterday, the GCAN CEO, Aitan Zacharin owns 230,533,304 shares, which represents 19.1% of GCAN. Mark Radom owns 130,533,304 shares which represents 10.8% of GCAN. Fernando Bisker owns 130,533,304 shares which represents 10.8% of GCAN. Jona Kalfa owns 130,533,304 shares which represents 10.8% of GCAN. Elisha Kalfa owns 130,533,304 shares which represents 10.8% of GCAN. Elisha Kalfa owns 130,533,304 shares which represents 10.8% of GCAN. Sigalush Ventures LLC owns 130,533,304 shares which represents 10.8% of GCAN: https://www.otcmarkets.com/filing/html?id=18437182&guid=AiV-kaQlROMcLhh
That's a total of 883,199,824 shares with the GCAN CEO, Aitan Zacharin, owning the largest single position of shares with having 230,533,304 shares. Collectively, they own 73.1% of GCAN based on what was filed as of April 7, 2025 (the “Record Date”).
It just doesn't make sense that they would not have their own best interest at heart and agree to do something like this to reverse split their shares to hurt themselves. I just find it hard that they would all agree to screw themselves like this. I can't help but lean towards something major coming in here that will still benefit us shareholders since the CEO and the Insiders are the largest shareholders by far as compared to any of us here. Also, the resume of the GCAN CEO strongly suggests that he as the connections to do some very big things. Why wouldn't he do something big with a stock where he and the Insiders own over 70% of the Outstanding Shares (OS)? It wouldn't surprise me if we see some kind of SPAC deal here with GCAN based of the CEO's resume below and since he's closing currently doing a $160 Million Core Gaming merger with SYTA:NASDAQ:
Mr. Zacharin is an experienced executive with broad knowledge in building and managing technology, biopharmaceutical, healthcare and consumer products businesses. Mr. Zacharin has founded a number of companies, and has seen them through successful listings in the public markets, with collective valuations of over $1 billion. Mr. Zacharin has been advising and investing in early to mid-stage startups, and assisting them with development, capitalization, accelerating growth, and turnaround strategies. He specializes in strategic acquisitions, structuring complex transactions, reverse mergers, and brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital raising and restructuring, debt financing, and mergers and acquisitions. In 2012 he co-founded Fuse Science, an innovative biotechnology company and was responsible for growth of the business from its conceptual stage to a publicly traded CPG and biotech business with multiple subsidiaries. He structured pivotal deals with key partners, which led to the company successfully raising over $20 million to commercialize its products, including brand ambassador agreements with 26 sports celebrities, including world renowned athlete Tiger Woods. He successfully exited from the company, which had reached a $110 million valuation. In 2014, Mr. Zacharin was appointed to the Board of Directors for Mediconecta, the largest telehealth Company in Latin America serving millions of patients with on-demand, high quality healthcare. Within six months, Mr. Zacharin facilitated and negotiated an eight figure buyout offer from Teladoc (NASDAQ: TDOC), the world’s largest telehealth company, just prior to its IPO. In 2015, Mr. Zacharin became the managing partner of Secure Hosting LLC, a blockchain mining company with a co-location mining farm in North Carolina. After two years of scaling out the operations to nearly $15,000,000 in assets, he successfully structured the sale of the company to a leading publicly traded blockchain mining company. In 2017, Mr. Zacharin founded GCANRx (OTC: GCAN), a publicly traded biopharmaceutical company focused on repurposing a highly bioavailable transmucosal drug delivery system that had previously been commercialized in partnership with Novartis. Mr. Zacharin repurposed the platform technology for use in cannabinoid therapeutics. He then negotiated a worldwide exclusive license from Shaare Zedek Scientific, the licensing arm of one of Israel’s largest research hospitals, for a cannabinoid-based therapeutic used in treating neuropsychiatric disorders. The therapeutic was invented by world-renowned cannabis researcher, Dr. Adi Aran, M.D. The Company is currently in the final stages of regulatory approval for a 100 patient Phase 2 clinical study for the treatment of autism related spectrum disorders. In 2018, Mr. Zacharin became a shareholder in sports technology company, Slinger (NASDAQ: CNXA). The company manufactures an innovative, patented sports product called the Slinger Bag, which raised $1 million through a highly successful Kickstarter campaign. Mr. Zacharin was tasked by the founder to take the company public. The Company was led by the past- CEO of global tennis company Prince. Within the first 18 months of operations the company grew to a global footprint of 65 countries, signed $250 million in distribution agreements, and achieved a market cap of over $400 million. Throughout the growth of the company, Mr. Zacharin served as the head of investor relations and was instrumental in raising the company over $27 million from leading Wall Street investors, and overseeing the IR strategy, which led to the stock rising over 1,700% from its listing price. Mr. Zacharin was actively involved in Slinger’s acquisition of three companies, most notably a Softbank and Verizon Ventures backed artificial intelligence sports company for $100 million. Mr. Zacharin led the effort of putting together a team, which successfully uplisted the Company from the OTC Markets to the Nasdaq. In 2019, Mr. Zacharin joined an investor group who acquired Solstice Sunglasses, the second largest sunglasses retailer in the US, to list the company’s shares on the public markets. Mr. Zacharin led the merger of Solstice with a public vehicle, which enabled a multi-million dollar round of financing for the retailer. In 2020, Mr. Zacharin identified, structured and facilitated the acquisition of a luxury, multi-state substance abuse facility. Mr. Zacharin secured financing for the $18 million acquisition with a combination of investments from high net worth individuals and a loan facility from a speciality banking lender. The company subsequently purchased two additional drug rehab portfolios, and grew to become a leading multi-state operator in the drug rehabilitation industry. In 2021, Mr. Zacharin became the co-founder and CEO of PlasmaCure, a groundbreaking medical device company focused on R&D and commercialization of an oncology treatment licensed from GW University. Mr. Zacharin holds dual degrees from the University of South Florida. He serves in an executive capacity to two publicly listed companies, and maintains various board non-profit board appointments.
AI
